Navigation Links
Hemispherx Presents Potential Avian Influenza Treatment,Breakthrough at Paris Conference

PARIS--(BUSINESS WIRE)--May 31, 2007 - Hemispherx Biopharma, Inc. (AMEX: HEB), a biopharmaceutical company engaged in the clinical development and manufacture of new drug entities for pandemic disease threats, announced today a new scientific report featuring its antiviral therapeutic product candidate Alferon-LDO in combating highly pathogenic avian influenza (HPAI), also known as "bird flu." Alferon-LDO is a low-dose experimental oral formulation of the Company's Alferon-N(TM) product, which is already approved by the United States FDA for the treatment of refractory genital warts (HPV).

The report concludes that Alferon-LDO appears to have potential as a preventive agent and/or treatment against avian influenza, reducing the severity of pathology resulting from infection of established animal model non-human primates (macaques) by a highly pathogenic strain of avian flu.

As noted in a 2006 Oxford University Clinical Research Unit study titled "Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia," illness caused by the avian influenza A virus stems most directly from the body's own response to infection, an overwhelming reaction sometimes termed a "cytokine storm." In the words of the Oxford University study, "high viral load, and the resulting intense inflammatory responses, are central to influenza H5N1 pathogenesis. The focus of clinical management should be on preventing this intense cytokine response, by early diagnosis and effective antiviral treatment."

To study the effects of Alferon-LDO, researchers administered macaque subjects with the drug via the animals' gum tissues, in a range of three dosing concentrations, with a fourth untreated group serving as a control. Following exposure of the dosed and untreated test subjects to the highly pathogenic HPAI strain A/Vietnam/1194/04, throat and nasal swabs were taken, gross pathology and viral lo ads were evaluated and representative samples of lung tissues were analyzed for pathologic changes.

Examination of the lungs revealed evidence of a dose-related reduction of infection-related pneumonia. Two of the three animals in the highest dosing group showed no evidence of lung infection to the naked eye, while lower-dose groups did show visible infection. This dose-related response was noteworthy given that viral loads were consistent among the subjects receiving the various dosages and the control group. Ten days of ongoing Alferon-LDO prophylaxis and treatment reduced the severity of pneumonia despite the continuing presence of the influenza virus.

The study results are being presented at the ongoing 2nd International Conference on Avian Influenza, being held at the Pasteur Institute.

Recent medical reports from critical influenza regions such as Southeast Asia indicate that presently available therapies, even given at the highest doses available via intravenous routes, do not alter the avian influenza death rate, which at present is greater than 60%. Given the danger of an avian flu pandemic, the lack of an effective available therapy and the fact that Alferon-N(TM) is already approved by the United States FDA as safe and effective in treating a different virus, Hemispherx management is hopeful that Alferon-LDO can receive expedited review and emergency-based approval as an anti-HPAI agent, solely relying on the "animal rule" for demonstration of efficacy.

"The threat of global pandemic illness from infectious disease puts the highest possible priority on finding therapeutic strategies that can protect first responders and save patient lives," commented Dr. William Carter, Chairman and Chief Executive Officer of Hemispherx. "We are encouraged by the strong potential that Alferon-LDO, an experimental formulation of our previously licensed drug, shows as a prophylactic agent, especially for front-line health care workers, and its ad ditional potential to effectively treat avian flu in those already infected."

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(R) and the experimental therapeutics Ampligen(R) and Oragens(R). Alferon N Injection(R) is approved for a category of STD infection, and Ampligen(R) and Oragens(R) represent experimental RNA nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N Injection(R)) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(R), Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications.

Contact

Hemispherx Biopharma, Inc.
Dianne Will, 518-398-6222
ir@hemispherx.net
or
Sean Collins, 310-477-9800
Sr. Partner
CCG Investor Relations


'"/>




Related medicine technology :

1. Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb 17, 2017 Research and Markets ... Business Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
(Date:2/17/2017)... ST. LOUIS , Feb. 17, 2017   ... hospitals, has announced a new partnership with Engage ... the United States . FormFast will serve ... part of Engage,s implementations with MEDITECH .  ... that provides essential functionality to complement and enhance the ...
(Date:2/17/2017)... 17, 2017 On Thursday, February ... edged lower at the closing bell, while the Dow ... 20,000 benchmark. Moreover, five out of nine sectors ended ... yesterday,s market sentiment, Stock-Callers.com assessed the following Medical Appliances ... (NYSE: SNN ), ABIOMED Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital is ... Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital within ... nation. While many providers are struggling to leverage limited resources and technology, Onslow Memorial ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason ... to families and business owners in and around the Hampton Roads metropolitan region, ... prevent all forms of domestic violence. , There are multiple categories of domestic ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha Chigurupati knows the ... research, development and clinical trials, the founder of Chigurupati Technologies has invented India’s ... FDA approved ingredients that when infused into alcohol, protect the consumer’s liver and ...
(Date:2/16/2017)... ... February 17, 2017 , ... Teaching nursing care of vulnerable children is the ... (pediatrics) is being created with the support of the Hearst Foundations. An initiative of ... will address what has been identified as a critical gap in preparing the next ...
(Date:2/16/2017)... ... February 16, 2017 , ... As a reflection of ... NWH has achieved Magnet® recognition for the second time, announced by ... American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet rigorous standards ...
Breaking Medicine News(10 mins):